University of California, San Francisco

550 16th St
San Francisco, CA 94158
United States
Call 844-813-8273 Email this location

University of California, San Francisco (UCSF) is one of twenty-five Type 1 Diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Stephen Gitelman, MD, the TrialNet team at UCSF is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Our Team

Principal Investigators 
Stephen
Gitelman
MD
Srinath
Sanda
MD
Co-Investigator
Christine
Ferrara
MD, PhD
Co-Investigator
Research Coordinators 
Christine
Torok
Study Coordinator
Glenna
Auerback
Study Coordinator
Martha
Rangel-Lugo
Study Coordinator
Rebecca
Wesch
Study Coordinator
Sheila
Ghods
Study Coordinator
Tracy
Rodriguez
Clinical Research Manager
"Our study participants are, by far, my favorite part of my job.   I love working with them and am in awe of everything that they handle every single day.  All participants manage their diabetes 24 hours a day, 7 days a week.  On top of that, they give of their time and energy to partake in one of our research studies.  Without them, there would be no TrialNet." – Christine Torok

Regional Affiliates

Affiliates provide opportunities for people who do not live near a TrialNet Clinical Center. The affiliate sites listed below work with UCSF to offer convenient participation in our research programs
Beverly Hills

University of Southern California
150 N. Robertson Blvd. Ste 210, Beverly Hills, CA 90211

Bonita

Southern California Permanente Medical Group
3955 Bonita Road, Bonita, CA 91902

Concord

John Muir Physician Network Clinical Research Center
2700 Grant Street Suite 202, Concord, CA 94520

Escondido

AMCR Institute, Inc.
625 West Citricado Pkwy, Suite 112, Escondido, CA 92026

Honolulu

East-West Medical Research Institute
1585 Kapiolani Blvd, #1500, Honolulu, HI 96814

La Jolla

The Whittier Institute for Diabetes
9898 Genesee Ave., 6th Floor, La Jolla, CA 92037

Las Vegas

Palm Research Center, Inc
9280 W. Sunset Rd, Suite 306, Las Vegas, NV 89148

Los Angeles

White Memorial Medical Center
1720 Cesar E. Chavez Ave., Los Angeles, CA 90033

Los Angeles

Childrens Hospital Los Angeles
4650 Sunset Blvd., Los Angeles, CA 90027

Oakland

Childrens Hospital and Research Center at Oakland
747 52nd St., Oakland, CA 94609

Phoenix

Phoenix Childrens Hospital
1919 E Thomas Road, Phoenix, AZ 85016

Sacramento

Center for Excellence in Diabetes and Endocrinology
3814 Auburn Blvd. Suite 72, Sacramento, CA 95821

Sacramento

Sutter Institute for Medical Research
2801 Capitol Ave, Suite 210, Sacramento, CA 95816

Sacramento

UC Davis, Pediatric Endocrinology
2516 Stockton Blvd., Sacramento, CA 95817

San Diego

Pediatric Endocrinology of San Diego
7920 Frost St., Ste 304B, San Diego, CA 92123

Torrance

SoCal Diabetes
3400 Lomita Blvd, Suite 209, Torrance, CA 90505

Tucson

University of Arizona Pediatric Endocrinology
1501 N Campbell Ave, Tucson, AZ 85724

Walnut Creek

Diablo Clinical Research, Inc.
2255 Ygnacio Valley Road, Suite M, Walnut Creek, CA 94598

"We strive every day to make real differences in the lives of people with type 1 diabetes and their families. TrialNet makes that possible. Seeing these families equally invested in and dedicated to the research is incredibly inspiring." Tracy Rodriguez, UCSF Clinical Research Manager

Research Studies

Risk Screening

Pathway to Prevention

If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.

More

Prevention Study

Abatacept

TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.

More

Teplizumab

We are testing the drug teplizumab to see if it can delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.

More

Longterm

Long-Term Investigative Follow-Up in TrialNet (LIFT)

Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.

More

"The ultimate goal is to be able to screen and predict who is at risk for diabetes, and then have an efficient way to turn off the disease process, before T1D ever happens!"-Stephen Gitelman, MD, UCSF Principal Investigator